Brainaurora-b
HKSE: 6681.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Equipment & Services
- CEO
- Longjun Cai
- Employees
- 159
- Headquarters
- Shaoxing, China
- IPO year
- 2025
- Market cap
- HK$5.3B
- Website
- https://66nao.cn
Loading 6681…
Loading profile data…Frequently asked questions about 6681
What does Brainaurora-b (6681.HK) do?
BrainAurora Medical Technology Limited develops medical-grade digital therapy (DTx) products for cognitive impairment. The company offers the evaluation and intervention of cognitive impairments to treat vascular diseases, neurodegenerative diseases, psychological disorders, and child development deficiencies. It develops the Brain Function Info...
Where does 6681.HK trade?
Brainaurora-b (6681.HK) trades on the Hong Kong Stock Exchange.
What sector is 6681.HK in?
Brainaurora-b (6681.HK) operates in the Healthcare sector, specifically in the Medical - Equipment & Services industry.
Who is the CEO of Brainaurora-b?
Longjun Cai is the chief executive officer of Brainaurora-b (6681.HK).
Where is Brainaurora-b headquartered?
Brainaurora-b is headquartered in China.
Does 6681.HK pay a dividend?
Brainaurora-b (6681.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6681.HK go public?
Brainaurora-b (6681.HK) completed its initial public offering in 2025.